Rigel Pharmaceuticals, Inc. - Common Stock (NQ:RIGL)

40.54 +0.89 (+2.25%)

Delayed Quote Updated: 12:23 PM EST, Nov 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Rigel Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Rigel Pharmaceuticals Q3 Earnings Call Highlights ↗

November 06, 2026

Rigel Pharmaceuticals (NASDAQ:RIGL) reported record quarterly product sales in the third quarter of 2026, helped by the launch of breast cancer treatment VEPPANU, while net income declined as spending...

Via MarketBeat

Topics Earnings

Rigel (RIGL) Q3 2026 Earnings Call Transcript ↗

November 06, 2026

VEPPANU launch lifts sales while R289 advances toward 2027 trials.

Via The Motley Fool

Topics Earnings

Rigel (RIGL) Q2 2026 Earnings Call Transcript ↗

August 11, 2026

VEPPANU launch and R289 data readouts drive second-half priorities.

Via The Motley Fool

Topics Earnings

Rigel Pharmaceuticals (NASDAQ:RIGL) Q1 2026 Results Miss Revenue and EPS Estimates, Stock Declines After-Hours ↗

May 05, 2026

Via Chartmill

RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL): A GARP Stock with Affordable Growth and Strong Fundamentals ↗

January 21, 2026

Via Chartmill

Rigel Pharmaceuticals Inc (NASDAQ:RIGL) Shows Strong Growth and Technical Momentum ↗

December 31, 2025

Via Chartmill

Rigel Pharmaceuticals Q2 Earnings Call Highlights ↗

August 04, 2026

Rigel Pharmaceuticals (NASDAQ:RIGL) reported second-quarter 2026 total revenue of $78.7 million and net income of $17.3 million, while outlining plans to launch newly licensed breast cancer therapy...

Via MarketBeat

Topics Earnings

These Analysts Increase Their Forecasts On Arvinas After Q1 Results ↗

May 13, 2026

Arvinas Inc (NASDAQ:ARVN) reported Q1 losses of 90 cents/share, missed analyst estimates. Rigel Pharmaceuticals (NASDAQ:RIGL) announced global licensing agreement with Arvinas and Pfizer (NYSE:PFE) for...

Via Benzinga

Why One Fund’s $4 Million Centerra Gold Exit Looks Like Profit-Taking Amid a 150% Rally ↗

May 10, 2026

Centerra Gold operates integrated mining projects in North America and Turkey, generating revenue from gold, copper, and molybdenum sales.

Via The Motley Fool

This Fund Cashed Out of Preformed Line Products Amid a 150% Stock Surge ↗

May 08, 2026

Preformed Line Products designs and manufactures network hardware for utilities and telecoms across global infrastructure markets.

Via The Motley Fool

Topics Regulatory Compliance Supply Chain

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

Rigel Pharmaceuticals Inc (NASDAQ:RIGL) Presents a Compelling Case for Value Investors ↗

October 27, 2025

Via Chartmill

Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data ↗

March 16, 2026

Today, March 16, 2026, investors weigh striking early colorectal cancer results against weak quarterly numbers and a finite cash runway.

Via The Motley Fool

Topics Stocks

Rigel Pharma (RIGL) Earnings Call Transcript ↗

March 03, 2026

Rigel Pharma (RIGL) Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) Emerges as a Top Affordable Growth Stock ↗

December 16, 2025

Rigel Pharmaceuticals (RIGL) presents a strong GARP investment case with high growth, solid profitability, and a notably low valuation compared to its biotech peers.

Via Chartmill

RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL) Presents a Strong 'Decent Value' Investment Case ↗

December 13, 2025

Rigel Pharmaceuticals (RIGL) presents a strong value investment case with a very low P/E ratio, robust financial health, and high earnings growth potential.

Via Chartmill

RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL) Meets Minervini Trend Template and High-Growth Momentum Criteria ↗

December 02, 2025

Rigel Pharmaceuticals (RIGL) aligns with Mark Minervini's growth strategy, showing a strong technical uptrend supported by accelerating earnings and revenue momentum.

Via Chartmill

RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL): A GARP Investment with Strong Growth and a Reasonable Price ↗

November 24, 2025

Discover Rigel Pharmaceuticals (RIGL), a GARP stock with explosive growth, a low P/E ratio, and strong financials, offering value in the biotech sector.

Via Chartmill

Keep an eye on the top gainers and losers in Wednesday's session. ↗

November 05, 2025

Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

November 05, 2025

Via Benzinga

Johnson Controls, Babcock & Wilcox, Lemonade, Lumentum, Teva Pharmaceutical And Other Big Stocks Moving Higher On Wednesday ↗

November 05, 2025

Via Benzinga

Wednesday's session: gap up and gap down stocks ↗

November 05, 2025

Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session.

Via Chartmill

These stocks that are showing activity before the opening bell on Wednesday. ↗

November 05, 2025

The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 05, 2025

Via Benzinga

Why Teradata Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ↗

November 05, 2025

Via Benzinga

What's going on in today's after hours session ↗

November 04, 2025

Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

November 04, 2025

Via Benzinga

A Look Ahead: Rigel Pharmaceuticals's Earnings Forecast ↗

November 03, 2025

Via Benzinga

Rigel Pharmaceuticals Inc (NASDAQ:RIGL) Shows Strong Alignment with Navellier's Growth Criteria ↗

October 29, 2025

Rigel Pharmaceuticals shows explosive growth, strong cash flow, and high ROE, aligning with Louis Navellier's proven stock-picking system for growth investors.

Via Chartmill

RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL) Combines Strong Growth and Bullish Technicals ↗

October 21, 2025

RIGL stock shows strong revenue & earnings growth with a low P/E ratio. Its technical chart pattern suggests a potential breakout from a recent trading range.

Via Chartmill

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.